Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator.
Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal
Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tiss
Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian
The European Commission has approved SIFI's Akantior as the first therapy anywhere in the world for acanthamoeba keratitis (AK), an ultra-rare parasitic infection that can lead to blindness
Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to manufa